MDxHealth has signed an exclusive pharma licensing agreement with Teva Pharmaceuticals for commercialization of ConfirmMDx for Prostate Cancer and PredictMDx for Glioblastoma tests in Israel.
ConfirmMDx provides physicians with actionable information that helps improve patient care, particularly the avoidance of unnecessary repeat prostate biopsies.
The PredictMDx test is used to identify glioma patients who have methylation of the MGMT (O6-Methylguanine-DNA Methyltransferase) gene. In clinical studies, these patients have shown the potential to respond better to certain chemotherapeutic drugs.
Teva Pharmaceuticals Industries will be the exclusive distributor of both tests in Israel.
Samples will be sent to MDxHealth's CLIA-registered laboratory in Irvine, California for analysis.
Teva will reimburse MDxHealth for all the testing services.
View the full article at MarketWatch
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Teva
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity